290 related articles for article (PubMed ID: 12379707)
1. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
Murray HW; Lu CM; Mauze S; Freeman S; Moreira AL; Kaplan G; Coffman RL
Infect Immun; 2002 Nov; 70(11):6284-93. PubMed ID: 12379707
[TBL] [Abstract][Full Text] [Related]
2. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
Murray HW
Acta Trop; 2005 Mar; 93(3):295-301. PubMed ID: 15716043
[TBL] [Abstract][Full Text] [Related]
4. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response.
Melby PC; Chandrasekar B; Zhao W; Coe JE
J Immunol; 2001 Feb; 166(3):1912-20. PubMed ID: 11160239
[TBL] [Abstract][Full Text] [Related]
5. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
[TBL] [Abstract][Full Text] [Related]
6. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.
Murray HW; Flanders KC; Donaldson DD; Sypek JP; Gotwals PJ; Liu J; Ma X
Infect Immun; 2005 Jul; 73(7):3903-11. PubMed ID: 15972476
[TBL] [Abstract][Full Text] [Related]
7. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.
Murray HW
Infect Immun; 2008 Sep; 76(9):4088-91. PubMed ID: 18573898
[TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.
Alexander J; Carter KC; Al-Fasi N; Satoskar A; Brombacher F
Eur J Immunol; 2000 Oct; 30(10):2935-43. PubMed ID: 11069076
[TBL] [Abstract][Full Text] [Related]
9. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity.
Stäger S; Alexander J; Carter KC; Brombacher F; Kaye PM
Infect Immun; 2003 Aug; 71(8):4804-7. PubMed ID: 12874364
[TBL] [Abstract][Full Text] [Related]
10. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
[TBL] [Abstract][Full Text] [Related]
11. IL-10 mediates susceptibility to Leishmania donovani infection.
Murphy ML; Wille U; Villegas EN; Hunter CA; Farrell JP
Eur J Immunol; 2001 Oct; 31(10):2848-56. PubMed ID: 11592059
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
Murray HW; Montelibano C; Peterson R; Sypek JP
J Infect Dis; 2000 Nov; 182(5):1497-502. PubMed ID: 11023473
[TBL] [Abstract][Full Text] [Related]
13. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
14. Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.
Murray HW; Hariprashad J; McDermott DF; Stoeckle MY
Infect Immun; 1996 Jan; 64(1):161-6. PubMed ID: 8557335
[TBL] [Abstract][Full Text] [Related]
15. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani.
Melby PC; Yang YZ; Cheng J; Zhao W
Infect Immun; 1998 Jan; 66(1):18-27. PubMed ID: 9423834
[TBL] [Abstract][Full Text] [Related]
16. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.
Murray HW; Hariprashad J; Coffman RL
J Exp Med; 1997 Mar; 185(5):867-74. PubMed ID: 9120392
[TBL] [Abstract][Full Text] [Related]
17. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.
Murray HW; Lu CM; Brooks EB; Fichtl RE; DeVecchio JL; Heinzel FP
Infect Immun; 2003 Nov; 71(11):6453-62. PubMed ID: 14573667
[TBL] [Abstract][Full Text] [Related]
18. Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.
Murray HW; Zhang Y; Zhang Y; Raman VS; Reed SG; Ma X
Infect Immun; 2013 Jul; 81(7):2318-26. PubMed ID: 23589575
[TBL] [Abstract][Full Text] [Related]
19. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Rα-responsive macrophages and neutrophils.
McFarlane E; Carter KC; McKenzie AN; Kaye PM; Brombacher F; Alexander J
J Infect Dis; 2011 Jul; 204(1):36-43. PubMed ID: 21628656
[TBL] [Abstract][Full Text] [Related]
20. Visceral Leishmania donovani infection in interleukin-13-/- mice.
Murray HW; Tsai CW; Liu J; Ma X
Infect Immun; 2006 Apr; 74(4):2487-90. PubMed ID: 16552085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
